B
Bull
Bull · 25%IRWD
$0.52
Szenariopreis
$4.130
-0.107 (-2.59%)Zum Schluss
Loading chart…
- High
- 4.210
- Open
- 4.200
- VWAP
- 4.14
- Vol
- 1.52M
- Mkt Cap
- 985.53M
- Low
- 4.080
- Amount
- 6.29M
- EV/EBITDA, TTM
- 2.92
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
AI analysis of Ironwood Pharmaceuticals Inc (IRWD)
holdIronwood Pharmaceuticals Inc (IRWD) is currently a hold. The stock price of $4.13 is near key support levels, and while it has shown impressive growth over the past year (+215.27%), the recent insider selling has increased significantly by 22659.51%.
Analyst Ratings (11)
+50.85% upside
Buy
5 Buy
5 Hold
1 Sell
Current: 4.13
Tief
5.00
Durchschnitt
6.23
Hoch
8.00
Citizens
Outperform
$10
2026-02-26
Citizens
2026-02-26
Kursziel
$10
Outperform
Craig-Hallum
Buy
—
2026-01-05
Craig-Hallum
2026-01-05
Kursziel
—
Buy
Citizens
Outperform
$8
2026-01-05
Citizens
2026-01-05
Kursziel
$8
Outperform
Wells Fargo
Equal Weight
$5
2026-01-04
Wells Fargo
2026-01-04
Kursziel
$5
Equal Weight
Craig-Hallum
Hold
—
2025-11-26
Craig-Hallum
2025-11-26
Kursziel
—
Hold
Bewertungskennzahlen
The current forward P/E ratio for Ironwood Pharmaceuticals Inc (IRWD) is 12.33, compared to its 5-year average forward P/E of 14.70.
Alphio AI Price Scenarios for IRWD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IRWD
Event-Zeitleiste
News
2.008-13NASDAQ.COMIronwood (IRWD) Q2 2026 Earnings Call Transcript
5.007-14NASDAQ.COMIronwood Pharmaceuticals Appoints New CMO
8.505-29NASDAQ.COMRegulatory Approvals and Collaborations in Biotech Sector
9.005-28NASDAQ.COMFDA Approves LINZESS for Pediatric Functional Constipation Treatment
8.505-27seekingalphaFDA Approves Linzess Label Expansion for Children
IRWD FAQ — answered by Alphio AI
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ironwood Pharmaceuticals Inc (IRWD) is currently a hold. The stock price of $4.13 is near key support levels, and while it has shown impressive growth over the past year (+215.27%), the recent insider selling has increased significantly by 22659.51%.
11 analysts cover IRWD: 5 rate it Buy, 5 Hold and 1 Sell. The average price target is 6.23.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.